Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 29, 2019

Study Completion Date

November 9, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

Ixazomib

"Cycle 1:~Ixazomib: 4mg/day 1, 8, 15~Cycles 2-6:~Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"

DRUG

Cyclophosphamide

"Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily"

DRUG

Dexamethasone

"Cycle 1:~Dexamethasone: 20 mg/day 1, 8, 15~Cycles 2-6:~Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18"

Trial Locations (3)

02860

Memorial Hospital of Rhode Island, Pawtucket

02903

Rhode Island Hospital, Providence

02906

The Miriam Hospital, Providence

All Listed Sponsors
collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

collaborator

Memorial Hospital of Rhode Island

OTHER

lead

John L. Reagan

OTHER

NCT02412228 - Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma | Biotech Hunter | Biotech Hunter